30Sep
30Sep
Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced it presented new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) targeting myeloid-derived suppressor cells (MDSCs) at Cambridge Healthtech Institute’s Inaugural Targeting Tumor Myeloid Cells Conference, held September 27-28, 2017 in Boston. Read more >>
27Sep
Bible Hill woman hopes to raise funds for a device that can enhance her vision
Most of us take such things for granted – reading print at a comfortable distance, identifying which car is yours in the parking lot or comprehending what another person is doing just across the room. Advertisement For Tammy Martin, the ability to perform such feats stirs a sense of awe. Tammy was born with optic nerve hypoplasia, a condition where the optic nerves are underdeveloped. She has poor depth perception and everything appears very small, as if she were a considerable distance away....
25Sep
Wearable assistive technology will hit the runway at Invictus showcase
Electronic glasses for the visually impaired — including people who haven’t been able to see their entire lives — will be among the 48 exhibits at this week’s Accessibility Innovation Showcase, an official event of the 2017 Invictus Games. Read more >>
24Sep
Poplar Grove student doesn’t mind standing out in a crowd if it means better learning
Ellie Leden sticks out in a second-grade classroom because of her headgear. She doesn’t mind. After all, she sees a lot better than she did last year. Read more >>
22Sep
Turning over a new leaf
Ingredients obtained by KnipBio from specialised strains of leaf symbiont bacteria have been demonstrated to offer promising alternatives to fishmeal in aquafeeds, following a number of recent trials. Read more >>
21Sep
Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology ("ACR") 2017 Annual Meeting being held November 3-8, 2017 in San Diego, California. Read more >>
21Sep
VisionCorps offers visually impaired chance to try eSight & NuEyes electronic smart glasses
On Oct. 5, VisionCorps is inviting the public to come try electronic smart glasses designed to help those with severe visual impairments see better. The VisionCorps Foundation purchased one eSight and three NuEyes units to use for demonstrations and studying their impact on workers at the VisionCorps manufacturing, food processing and administrative businesses. Read more >>
20Sep
Aras $39.50 million Fundraising. Peter Schroer Released Sep 19 form
Aras Corp, Corporation just submitted form D for $39.50 million equity financing. This is a new filing. Aras was able to finance itself with $39.50 million. That is 100.00 % of the fundraising. The total private financing amount was $39.50 million. The financing document was filed on 2017-09-19. The reason for the financing was: unspecified. Read more >>
20Sep